Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 Monoclonal Antibody + Lenalidomide in Advanced Colorectal Cancer
NCT04326296Phase 1Unknown
- Sponsor
- Li-Ning
- Start
- May 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in colorectal cancer (CRC), sponsored by Li-Ning. Primary endpoints: Disease control rate at 1 year and Safety, Tolerability at 1.5 years. Status: unknown.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04326296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326296.